Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Phase 4
Completed
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Registration Number
- NCT00432393
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration).
Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- age greater than 50 years old
- first ophthalmic examination within 6 weeks after onset of disease
- presence of optic disc swelling followed by optic atrophy within 6 weeks
- altitudinal, central or generalized visual field defect
- normal ESR
Exclusion Criteria
- confirmed giant cell arteritis
- history of any ocular surgeries
- optic neuropathy due to acute bleeding
- advanced diabetic retinopathy
- uncontrolled glaucoma
- any ocular disorders that cause visual acuity reduction rather than NAION
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ophthalmic research center
🇮🇷Tehran, Iran, Islamic Republic of